Study of pembrolizumab and lenvatinib for lung papillomas
Treatments studied
Part of Lungs & breathing clinical trials.
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have confirmed respiratory papillomas (from a biopsy/cytology test) with signs on imaging of lung involvement
- Have HPV-related disease confirmed by lab testing (in-situ hybridization and/or PCR)
- Provide a new biopsy tissue sample (or an approved stored sample) within 6 weeks before starting treatment
- Have adequate blood counts and organ function based on lab tests (for example, enough white blood cells, platelets, and kidney/liver numbers)
- Be able to do daily activities normally most of the time (ECOG 0–1) and have controlled blood pressure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests combining two drugs, bevacizumab and PRGN-2012, to treat recurrent respiratory papillomatosis (RRP), a condition where non-cancerous growths come back in the airway. The goal is to see if the combination reduces the need for surgeries or other procedures.
This trial tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for women with advanced vulvar cancer that cannot be surgically removed or has spread. The goal is to see if this combination can shrink or control the cancer.
This trial tests whether adding two drugs—pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy)—to the standard chemoradiation and brachytherapy can improve outcomes for women with high-risk locally advanced cervical cancer. The goal is to see if this combination helps control the cancer better than usual treatment.
Hear when a new Human Papilloma Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.